Guazzieri S, Lembo A, Ferro G, Artibani W, Merlo F, Zanchetta R, Pagano F
Urology. 1985 Aug;26(2):139-42. doi: 10.1016/0090-4295(85)90046-9.
The level of antisperm antibodies using the enzyme-linked immunosorbent assay (ELISA) in the serum of 48 patients with testicular cancer before and after therapy is reviewed. This is not a linear study of each patient, but some conclusions can be drawn: In a high percentage of testicular cancer patients serum antisperm antibodies can be detected: 73.3 per cent before orchiectomy and 43.7 per cent overall. The percentage of patients with antibodies decreases with adequate therapy. In patients with advanced disease there is a higher percentage of positivity (50%) for serum antisperm antibodies than in patients with low-stage disease (30%). The higher percentage of antibodies-positive patients among those with infertility patterns could be an important argument that supports the hypothesis that autoimmune pathology can play a role in oligo/azoospermia in testicular cancer patients.
回顾了48例睾丸癌患者治疗前后血清中使用酶联免疫吸附测定（ELISA）检测抗精子抗体的水平。这不是对每个患者的线性研究，但可以得出一些结论：在高比例的睾丸癌患者中可检测到血清抗精子抗体：睾丸切除术前为73.3%，总体为43.7%。抗体患者的比例随着适当治疗而降低。在晚期疾病患者中，血清抗精子抗体阳性率（50%）高于低分期疾病患者（30%）。在有不育模式的患者中抗体阳性患者比例较高，这可能是一个重要论据，支持自身免疫病理可能在睾丸癌患者少精/无精症中起作用这一假说。
